Overview

FTIH - Single and Repeat Oral Doses of FDL169 in Healthy Volunteers

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of single and multiple escalating doses of FDL169 in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Flatley Discovery Lab LLC